ACR – The window to early kidney disease
PROF. TROND JENSSEN
Professor of Nephrology in the Department of Clinical Medicine, University of Oslo, and leader of the Research Group for Transplantation Medicine, Section of Nephrology, Rikshospitalet, Oslo University Hospital
제시된 견해와 의견은 저자의 것입니다. 이 웹캐스트에 포함된 콘텐츠는 정보 제공/교육 목적으로만 사용됩니다.
Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1. Early detection can slow disease progression or even prevent it altogether1 — which is why testing in at-risk groups is so important.
Join this livestream series of 20 minutes each to learn how early detection can slow disease progression or even prevent it valtogether.
Our international speakers will discuss the role of rapid diagnostics in disease prevention, with point-of-care testing such as an Albumin Creatinine Ratio (ACR) assay, enabling healthcare providers to detect, and treat, kidney disease in minutes.
Learn more about current guidelines and kidney disease prevention and management.
Series of six livestream events covering:
- Importance of regular testing for early detection and monitoring in high-risk patients
- Importance of ACR testing beside the determination of eGFR
- Latest guidance on disease prevention and management
- Case studies
© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. Products available in select markets only. COL-16422 01/2023